1. ？Panos RJ,Mortenson RL,Niccoli SA,et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis:causes and assessment. Am J Med,1990,88:396-404.
[3]
2. Olson AL,Swigris JJ,Lezotte DC,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
[4]
3. Kohno N,Kyoizumi S,Awaya Y,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydratel antigen KL-6. Chest,1989,96:68-73.
[5]
4. Ohshimo S,Yokoyama A,Hattori N,et al.KL-6,a human MUC1 mucin,promotes proliferation and survival of lung fibrosis.Biochem Biophys Res Commun,2005,338:1845-1852.
[6]
5. Raghu G,Collard HR,Egan JJ,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
8. Xu L,Yan DR,Zhu SL,et al. KL-6 regulated the expression of HGF,collagen and myofibroblastdifferentiation. Eur Rev Med Pharmacol Sci,2013,17:3073-3077.
[9]
9. Kitamura S,Hiwada K,Kobayashi J,et al. Use of the ED046 kit to analyze serum KL-6 in patients with pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi,1996,34:639-645.
[10]
10. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest,1999,46:151-158.
